GlassScriptPhysician profile
Katherine A Panice
NPI 1619321718
$7,860.29
in general payments reported to CMS, 2019-2025
32 companies · $2,339 in 2025
The $2,339 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $999 · 2022: $1,391 · 2023: $1,604 · 2024: $1,527 · 2025: $2,339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,470.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,469.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,557.11 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $789.48 | 2021-2025 | Tezspire, Breztri, Fasenra |
| Grifols USA, LLC | $699.79 | 2022-2025 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $567.82 | 2021-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Regeneron Healthcare Solutions, INC. | $493.30 | 2022-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $420.70 | 2021-2025 | Opsumit, Uptravi |
| Takeda Pharmaceuticals U.S.A., INC. | $417.10 | 2021-2025 | Glassia |
| Avadel Cns Pharmaceuticals, LLC | $342.45 | 2023-2025 | Lumryz |
| Jazz Pharmaceuticals INC. | $309.26 | 2021-2025 | |
| Genzyme Corporation | $275.22 | 2023-2025 | |
| Mylan Specialty L.P. | $252.61 | 2021-2024 | Yupelri |
| Insmed, INC. | $228.37 | 2024-2025 | Arikayce, Brinsupri |
| Viatris Specialty LLC | $150.36 | 2025 | Yupelri |
| Verona Pharma, INC. | $148.27 | 2025 | Ohtuvayre |
| Novartis Pharmaceuticals Corporation | $145.73 | 2021-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $138.87 | 2022-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Axsome Therapeutics, INC. | $130.88 | 2022-2025 | Sunosi |
| Electromed, INC. | $118.10 | 2021-2025 | Smartvest |
| Harmony Biosciences LLC | $106.84 | 2023-2024 | Wakix |
| Philips North America LLC | $101.80 | 2024-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Inspire Medical Systems, INC. | $69.85 | 2025 | Inspire |
| Inogen, INC. | $67.17 | 2023-2025 | Inogen At Home Stationary Concentrator, Inogen One G3 Oxygen Concentrator |
| Melinta Therapeutics, LLC | $62.68 | 2023 | Vabomere, Rezzayo |
| Lilly USA, LLC | $58.18 | 2025 | Zepbound |
| Teva Pharmaceuticals USA, INC. | $42.21 | 2021 | |
| Merck Sharp & Dohme LLC | $34.35 | 2021-2022 | |
| Vapotherm INC | $30.86 | 2022 | |
| Advanced Respiratory, INC | $24.99 | 2021 | |
| Arbor Pharmaceuticals, INC. | $23.61 | 2021-2022 | |
| Pulmonx Corporation | $20.69 | 2022 | |
| Azurity Pharmaceuticals, INC. | $18.48 | 2023 | Horizant |
| Abbvie INC. | $13.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Panice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.